CN102802627A - 电压门控的钠通道阻滞剂 - Google Patents

电压门控的钠通道阻滞剂 Download PDF

Info

Publication number
CN102802627A
CN102802627A CN2011800141112A CN201180014111A CN102802627A CN 102802627 A CN102802627 A CN 102802627A CN 2011800141112 A CN2011800141112 A CN 2011800141112A CN 201180014111 A CN201180014111 A CN 201180014111A CN 102802627 A CN102802627 A CN 102802627A
Authority
CN
China
Prior art keywords
methyl
phenyl
methylethyl
piperazinyl
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800141112A
Other languages
English (en)
Chinese (zh)
Inventor
J.C.贝姆
R.S.戴维斯
J.K.科恩斯
林国良
聂红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44304640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102802627(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN102802627A publication Critical patent/CN102802627A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2011800141112A 2010-01-14 2011-01-13 电压门控的钠通道阻滞剂 Pending CN102802627A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29513810P 2010-01-14 2010-01-14
US61/295,138 2010-01-14
US31700510P 2010-03-24 2010-03-24
US61/317,005 2010-03-24
PCT/US2011/021114 WO2011088201A1 (en) 2010-01-14 2011-01-13 Voltage-gated sodium channel blockers

Publications (1)

Publication Number Publication Date
CN102802627A true CN102802627A (zh) 2012-11-28

Family

ID=44304640

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800141112A Pending CN102802627A (zh) 2010-01-14 2011-01-13 电压门控的钠通道阻滞剂

Country Status (24)

Country Link
US (1) US20130023541A1 (https=)
EP (1) EP2523665A4 (https=)
JP (1) JP2013517283A (https=)
KR (1) KR20120124064A (https=)
CN (1) CN102802627A (https=)
AR (1) AR079906A1 (https=)
AU (1) AU2011205302B2 (https=)
BR (1) BR112012017266A2 (https=)
CA (1) CA2787025A1 (https=)
CL (1) CL2012001971A1 (https=)
CO (1) CO6592051A2 (https=)
CR (1) CR20120402A (https=)
EA (1) EA201290644A1 (https=)
IL (1) IL220836A0 (https=)
MA (1) MA33987B1 (https=)
MX (1) MX2012008285A (https=)
NZ (1) NZ601126A (https=)
PE (1) PE20121518A1 (https=)
PH (1) PH12012501421A1 (https=)
SG (1) SG182400A1 (https=)
TW (1) TW201139406A (https=)
UY (1) UY33186A (https=)
WO (1) WO2011088201A1 (https=)
ZA (1) ZA201205126B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017133591A1 (zh) * 2016-02-03 2017-08-10 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
CN109796402A (zh) * 2018-12-28 2019-05-24 京博农化科技有限公司 一种烟嘧磺隆中间体2-氯-n，n-二甲基烟酰胺的制备方法
CN111548301A (zh) * 2019-02-08 2020-08-18 三星显示有限公司 稠合环状化合物及包含所述稠合环状化合物的有机发光装置

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2963028B1 (en) 2009-05-27 2018-08-01 Atir Holding S.A. Piperazine derivatives and their pharmaceutical use
KR101178181B1 (ko) * 2010-09-17 2012-09-19 대한민국(농촌진흥청장) 신규한 항생활성 화합물 및 그 화합물을 포함하는 항생 조성물
WO2012049555A1 (en) 2010-10-13 2012-04-19 Lupin Limited Spirocyclic compounds as voltage-gated sodium channel modulators
JP2014518281A (ja) * 2011-07-06 2014-07-28 グラクソ グループ リミテッド 電位依存性ナトリウムチャネル遮断薬
JP6014155B2 (ja) * 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
RU2014121984A (ru) * 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2643403T3 (es) 2011-12-28 2017-11-22 Global Blood Therapeutics, Inc. Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
EP2884978B1 (en) * 2012-08-16 2019-07-17 The Scripps Research Institute Novel kappa opioid ligands
ES2663798T3 (es) * 2013-03-14 2018-04-17 Daiichi Sankyo Company, Limited Fármaco para enfermedades respiratorias
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MX379235B (es) 2013-03-15 2025-03-11 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina.
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150258A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014150289A1 (en) * 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2015088864A1 (en) * 2013-12-09 2015-06-18 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists
JP6045487B2 (ja) * 2013-12-25 2016-12-14 シャープ株式会社 操作入力システム、電子機器、携帯端末、及び操作入力方法
CN114181195A (zh) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
EP3110794A1 (en) * 2014-02-27 2017-01-04 Merck Patent GmbH Heterocyclic compounds as nav channel inhibitors and uses thereof
MA39778A (fr) 2014-03-29 2017-02-08 Lupin Ltd Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
HK1252567A1 (zh) 2015-05-22 2019-05-31 基因泰克公司 被取代的苯甲酰胺和其使用方法
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
CA2999769A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
PE20190980A1 (es) 2016-10-17 2019-07-09 Genentech Inc Compuestos terapeuticos y metodos para utilizarlos
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
CN101326162A (zh) * 2005-10-10 2008-12-17 葛兰素集团有限公司 作为电压门控钠通道的调控剂的季铵化的α-氨基甲酰胺衍生物
CN101326163A (zh) * 2005-10-10 2008-12-17 葛兰素集团有限公司 作为钠通道调控剂的脯氨酰胺衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054305A1 (de) * 1998-04-20 1999-10-28 Basf Aktiengesellschaft Heterocyclisch substituierte amide als calpainhemmer
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
EP1638955A2 (en) * 2003-07-02 2006-03-29 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
EP1968968A1 (en) * 2005-12-21 2008-09-17 PainCeptor Pharma Corp. Compositions and methods for modulating gated ion channels
GEP20125379B (en) * 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101326162A (zh) * 2005-10-10 2008-12-17 葛兰素集团有限公司 作为电压门控钠通道的调控剂的季铵化的α-氨基甲酰胺衍生物
CN101326163A (zh) * 2005-10-10 2008-12-17 葛兰素集团有限公司 作为钠通道调控剂的脯氨酰胺衍生物
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THORSTEN ANGER 等: "Medicinal Chemistry of Neuronal Voltage-Gated Sodium Channel Blockers", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 44, no. 2, 18 January 2001 (2001-01-18), pages 115 - 137 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017133591A1 (zh) * 2016-02-03 2017-08-10 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
US10815197B2 (en) 2016-02-03 2020-10-27 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. N-sulfonyl benzamides as voltage-gated sodium channel inhibitors
CN109796402A (zh) * 2018-12-28 2019-05-24 京博农化科技有限公司 一种烟嘧磺隆中间体2-氯-n，n-二甲基烟酰胺的制备方法
CN111548301A (zh) * 2019-02-08 2020-08-18 三星显示有限公司 稠合环状化合物及包含所述稠合环状化合物的有机发光装置
US11818951B2 (en) 2019-02-08 2023-11-14 Samsung Display Co., Ltd. Condensed cyclic compound and organic light-emitting device including the same

Also Published As

Publication number Publication date
ZA201205126B (en) 2013-03-27
EP2523665A4 (en) 2013-07-03
KR20120124064A (ko) 2012-11-12
AU2011205302B2 (en) 2014-10-09
US20130023541A1 (en) 2013-01-24
MA33987B1 (fr) 2013-02-01
AU2011205302A1 (en) 2012-08-02
MX2012008285A (es) 2012-08-03
AR079906A1 (es) 2012-02-29
SG182400A1 (en) 2012-08-30
PE20121518A1 (es) 2012-12-12
WO2011088201A1 (en) 2011-07-21
IL220836A0 (en) 2012-08-30
PH12012501421A1 (en) 2017-08-09
JP2013517283A (ja) 2013-05-16
NZ601126A (en) 2014-10-31
EP2523665A1 (en) 2012-11-21
CA2787025A1 (en) 2011-07-21
EA201290644A1 (ru) 2012-12-28
CR20120402A (es) 2012-09-03
CL2012001971A1 (es) 2013-01-25
CO6592051A2 (es) 2013-01-02
UY33186A (https=) 2011-07-29
BR112012017266A2 (pt) 2016-04-19
TW201139406A (en) 2011-11-16

Similar Documents

Publication Publication Date Title
CN102802627A (zh) 电压门控的钠通道阻滞剂
JP7775430B2 (ja) Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体
TWI839461B (zh) Il-17a調節物及其用途
CN109195965B (zh) Wdr5蛋白质-蛋白质结合的抑制剂
TWI663153B (zh) 作為激酶抑制劑的胺基雜芳基苯甲醯胺
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
TWI657076B (zh) 經取代磺醯胺化合物
JP2021098703A (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
CN106164047B (zh) 作为阿立新受体拮抗剂的1,2-取代环戊烷
CN115490751A (zh) 因子d抑制剂
TW200848037A (en) New compounds
CN110520127B (zh) 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
CN103764148A (zh) 电压门控的钠通道阻滞剂
JP2017527569A (ja) オレキシン−１受容体の阻害剤としての治療用化合物
TW201734020A (zh) 布魯頓氏酪胺酸激酶抑制劑及其使用方法
CN107922407A (zh) 呼吸道合胞病毒抑制剂
WO2022048631A1 (zh) 一种具有抗肿瘤活性的化合物及其用途
JP2024534572A (ja) ナトリウムチャンネル活性化剤としてのピリジニルアセトアミド誘導体
WO2021218992A1 (zh) 取代的吡咯烷类化合物及其在药物中的应用
TWI881587B (zh) 類木瓜蛋白酶(PLpro)抑制劑
HK40065747A (zh) 用於治疗家族性自主神经功能障碍的噻吩并[3，2-b]吡啶-7-胺化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121128